At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 190 target
Drug / intervention
HLX43drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy
In Brief
A Phase 2 clinical trial evaluating HLX43 for Cervical Cancer and Ovarian Cancer. Currently recruiting, targeting 190 participants across 1 site.
Detailed Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Ovarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202520262027
First PostedJan 2025
Enrollment StartFeb 2025
TodayJul 2026
Primary CompletionDec 2026
Study CompletionJun 2027
First PostedJan 10, 2025
Enrollment StartFeb 20, 2025
Primary CompletionDec 31, 2026
Study CompletionJun 5, 2027
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 1.5 years agoPrimary completion in 6 months
Interventions
HLX43drug
HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.